NCT06982040 is a Phase 2 clinical trial of NTQ5082 capsules 100 mg in Primary IgA Nephropathy, sponsored by Nanjing Chia-tai Tianqing Pharmaceutical.

Who is sponsoring NCT06982040?

NCT06982040 is sponsored by Nanjing Chia-tai Tianqing Pharmaceutical.

What drugs are being tested in NCT06982040?

Interventions in NCT06982040: NTQ5082 capsules 100 mg, NTQ5082 capsules 200 mg, NTQ5082 capsules 300 mg, Placebo.

What condition does NCT06982040 study?

NCT06982040 studies Primary IgA Nephropathy.

Is NCT06982040 still recruiting?

NCT06982040 is currently not yet recruiting. Last updated 20 May 2025.

Last reviewed 2025-05-20 · How we verify

NCT06982040

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of NTQ5082 Capsules in the Treatment of Patients With Primary IgA Nephropathy

Not yet recruiting Phase 2 Last updated 20 May 2025

What this trial tests

Phase 2 trial testing NTQ5082 capsules 100 mg in Primary IgA Nephropathy in 80 participants. Not yet recruiting.

Timeline

1 May 2025

Primary endpoint
1 September 2026

1 September 2026

Quick facts

Lead sponsor	Nanjing Chia-tai Tianqing Pharmaceutical
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	80
Start date	1 May 2025
Primary completion	1 September 2026
Estimated completion	1 September 2026

Drugs / interventions tested

NTQ5082 capsules 100 mg — full drug profile →
NTQ5082 capsules 200 mg — full drug profile →
NTQ5082 capsules 300 mg — full drug profile →
Placebo

Conditions studied

Primary IgA Nephropathy — all drugs for Primary IgA Nephropathy →

Sponsor

Nanjing Chia-tai Tianqing Pharmaceutical — full company profile →

Who can join

18 and older, any sex, with Primary IgA Nephropathy. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The log-transformed ratio of 24-hour urine protein-to-creatinine ratio (24h-UPCR) compared to baseline after 12 weeks of treatment.
Time frame: Week 12

Sponsor's own description

NTQ5082 is a small molecule inhibitor of complement factor B (CFB) that inhibits the enzymatic activity of CFB, thereby blocking the alternative pathway of the complement activation cascade. It is being clinically developed for the treatment of primary IgA nephropathy The main objectives of the study were to assess the efficacy and safety of NTQ5082 capsules in the treatment of patients with primary IgA nephropathy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in Complement-Targeted Therapy for IgA Nephropathy.
Lu M, Li G. · · 2026 · PMID 41608159 · DOI 10.1159/000550108
Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation.
Barratt J, Garred P, Lafayette RA, Zhang H, et al · · 2026 · PMID 41550519 · DOI 10.1016/j.ekir.2025.11.029

Verify or expand the search:

Other recruiting trials for Primary IgA Nephropathy

Currently open trials in the same condition.

NCT06137768 — A Trial of HRS-5965 Tablets in Primary IgA Nephropathy · Phase 2 · active not recruiting
NCT05797610 — A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA · Phase 3 · recruiting
NCT04557462 — A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in P · Phase 3 · recruiting

Other Nanjing Chia-tai Tianqing Pharmaceutical trials

Trials by the same sponsor.

NCT07462130 — An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) · Phase 1, PHASE2 · not yet recruiting
NCT07393321 — A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HE · Phase 3 · not yet recruiting
NCT06977763 — Clinical Study on the Effectiveness and Safety of Succinylated Gelatin Injection · NA · not yet recruiting
NCT07182552 — Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants · Phase 1 · enrolling by invitation
NCT06977750 — Clinical Study on the Effectiveness and Safety of Succinylated Gelatin Electrolyte Sodium Acetate Injection · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06982040 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing Chia-tai Tianqing Pharmaceutical
Last refreshed: 20 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06982040.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing